https://www.selleckchem.com/products/NXY-059.html
We observed 5 patients with TCZ withdrawal one showing adverse drug reaction (neutropenia) and four with secondary failure. Patients achieving successful long-term maintenance with TCZ were significantly younger than those with secondary failure (p less then 0.05). In addition, RA patients with positive rheumatoid factor and anti-citrullinated peptide antibodies, experienced a significantly greater number of flares during our 2-year follow-up (p less then 0.01). Conclusions A progressive tapering of TCZ infusions may be possible for
Like
Comment
Share
